Dulaglutide
GLP-1 Receptor AgonistapprovedAlso known as: Trulicity, LY2189265
An FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes with proven cardiovascular benefits and convenient single-use pen delivery.
Overview
Dulaglutide is a long-acting GLP-1 receptor agonist developed by Eli Lilly, marketed as Trulicity. It consists of a modified GLP-1 analog linked to a modified human IgG4 Fc fragment, which extends its half-life to approximately 5 days, allowing once-weekly dosing. Approved by the FDA in 2014 for type 2 diabetes, dulaglutide became one of the best-selling GLP-1 RAs due to its convenient ready-to-use pen device that requires no mixing or needle handling. The REWIND trial demonstrated cardiovascular benefits even in patients without established cardiovascular disease, broadening its indication. Dulaglutide produces moderate weight loss (3-5 kg) as a secondary benefit.
Mechanism of Action
Dulaglutide activates the GLP-1 receptor through its modified GLP-1 analog component. The IgG4-Fc fusion prevents renal clearance and enables FcRn-mediated recycling, achieving a ~5-day half-life. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and activates central satiety centers. The GLP-1 analog portion contains amino acid substitutions that resist DPP-4 degradation while maintaining receptor binding affinity.
Molecular Formula
Fusion protein (~59.7 kDa)
Molecular Weight
59670 g/mol
Sequence
GLP-1(7-37) analog fused to modified human IgG4 Fc fragment via small peptide linker
Dosage Protocols
Dose Range
0.75mg – 4.5mg
Frequency
Once weekly
Route
subcutaneous
Cycle Length
Ongoing / chronic
Start at 0.75mg weekly. May increase to 1.5mg, then 3.0mg, then 4.5mg for additional glycemic control. Same day each week, any time of day, with or without meals.
Source: FDA prescribing information (Trulicity)
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
0.75mg or 1.5mg pre-filled pen
Last Updated
2026-02
Brand Trulicity (Eli Lilly). List price ~$900/mo without insurance. With insurance: $25-150 copay. Weekly injection.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Nausea | moderate |
| Diarrhea | mild |
| Vomiting | moderate |
| Abdominal pain | mild |
| Decreased appetite | mild |
| Injection site reaction | mild |
| Pancreatitis | severe |
Pros & Cons
Convenient once-weekly dosing with a ready-to-use pen requiring no mixing or visible needle
Proven cardiovascular benefit in REWIND trial, even in patients without established CVD
Effective HbA1c reduction (1.0-1.6%) with moderate weight loss
Well-established long-term safety profile with extensive post-marketing data
Less weight loss compared to semaglutide and tirzepatide
GI side effects common, particularly nausea during initiation
Not specifically approved for weight management (off-label for obesity)
Thyroid C-cell tumor boxed warning based on rodent data
Research Studies
🩸 Blood Work
HbA1c
Baseline blood sugar — GLP-1 therapy standard
Fasting Blood Glucose
Hypoglycemia monitoring
Lipid Panel
Baseline cholesterol and triglycerides
Kidney Function (BMP/CMP)
Monitor renal function
Thyroid Panel (TSH, T3, T4)
Thyroid C-cell tumor warnings
FDA-approved GLP-1 agonist (Trulicity). Weekly injection with standard GLP-1 bloodwork requirements.
Legal Status
FDA-approved (2014) for type 2 diabetes. Prescription-only. EMA-approved. Widely available globally with insurance coverage for T2DM.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Collagen Peptides
Bioactive peptide fragments derived from hydrolyzed collagen protein that support skin elasticity, joint health, bone density, hair/nail growth, and gut lining integrity through stimulation of endogenous collagen synthesis.